Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

322.28 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets

October 15, 2025

The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and...

Via MarketMinute

Topics Artificial Intelligence World Trade

What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗

October 10, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

Earnings Outlook For Krystal Biotech ↗

August 01, 2025

Via Benzinga

Analyst Expectations For Krystal Biotech's Future ↗

July 25, 2025

Via Benzinga

Peering Into Krystal Biotech's Recent Short Interest ↗

July 02, 2025

Via Benzinga

If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today ↗

September 25, 2025

Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market...

Via Benzinga

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today ↗

September 18, 2025

Via Benzinga

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin ↗

September 15, 2025

The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data.

Via Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

September 02, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts ↗

August 22, 2025

Via Benzinga

What Does the Market Think About Krystal Biotech? ↗

May 28, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗

August 18, 2025

Via Benzinga

What 8 Analyst Ratings Have To Say About Krystal Biotech ↗

August 05, 2025

Via Benzinga

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗

August 04, 2025

Via Benzinga

Krystal (KRYS) Q2 Profit Jumps 143% ↗

August 04, 2025

Via The Motley Fool

KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth ↗

August 04, 2025

Krystal Biotech (KRYS) Q2 2025 earnings beat estimates with $96M revenue and $1.29 EPS, driven by VYJUVEK success. Shares rose 4% pre-market.

Via Chartmill

Topics Earnings

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today ↗

July 30, 2025

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

July 17, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years ↗

July 04, 2025

Via Benzinga

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Topics Artificial Intelligence

Demystifying Krystal Biotech: Insights From 7 Analyst Reviews ↗

June 24, 2025

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

June 20, 2025

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗

May 26, 2025

Via Benzinga

The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts ↗

May 16, 2025

Via Benzinga

Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

May 14, 2025

These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next

Via MarketBeat

Topics Earnings

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗

May 09, 2025

Via Benzinga

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease ↗

April 30, 2025

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.